EntryPoint Capital’s Standard BioTools LAB Stock Holding History

EntryPoint Capital’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,607	Closed	-$31.5K	–	841
2025 Q4	$31.5K	Buy	+24,607	New	+$33.1K	0.01%	636
2025 Q2	–	Sell	-253,668	Closed	-$274K	–	718
2025 Q1	$274K	Buy	+253,668	New	+$356K	0.13%	376
2024 Q4	–	Sell	-113,867	Closed	-$220K	–	858
2024 Q3	$220K	Buy	+113,867	New	+$223K	0.13%	406

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

EntryPoint Capital's LAB Position: Q1 2026 in Review

EntryPoint Capital sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 24,607 shares — an estimated $31.5K sold.

EntryPoint Capital first reported a position in LAB in Q3 2024 and held it in 3 quarters. The position peaked at $274K in Q1 2025. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

EntryPoint Capital reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
EntryPoint Capital sold 24,607 Standard BioTools shares in Q1 2026, an estimated $31.5K.
EntryPoint Capital first reported a position in Standard BioTools in Q3 2024 and held it in 3 quarters.
EntryPoint Capital's Standard BioTools position peaked at $274K in Q1 2025.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.